Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

@article{Fenton2012DrospirenoneEthinylestradiol3,
  title={Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)},
  author={C. Fenton and K. Wellington and Marit D. Moen and D. M. Robinson},
  journal={Drugs},
  year={2012},
  volume={67},
  pages={1749-1765}
}
SummaryAbstractDrospirenone 3mg with ethinylestradiol 20µg (Yaz®) is a low-dose combined oral contraceptive (COC) administered in a regimen of 24 days of active tablets followed by a short hormone-free interval (4 days; 24/4 regimen). Drospirenone, unlike other synthetic progestogens used in COCs, is a 17α-spirolactone derivative and a 17α-spironolactone analogue with antimineralocorticoid and antiandrogenic properties. Drospirenone/ethinylestradiol 3mg/20µg (24/4) is approved in the US for the… Expand
View on Springer
22 Citations
Highly Influential Citations
1
Background Citations
4
Methods Citations
2

22 Citations

Citation Type

Citation Type

Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women.
A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg
Beyaz®: An Oral Contraceptive Fortified with Folate
Nomegestrol Acetate/Estradiol
Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study
Nomegestrol acetate/estradiol: a guide to its use in oral contraception
Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 µg ethinyl estradiol.
Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature.
Progestins in Combined Contraceptives
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.
...
1
2
3
...

References

SHOWING 1-10 OF 50 REFERENCES
Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol
  • P. Rosenbaum, W. Schmidt, +7 authors R. Heithecker
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
Added benefits of drospirenone for compliance
  • J. Foidart
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2005
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Ethinylestradiol/Drospirenone
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
...
1
2
3
4
5
...